Cite
HARVARD Citation
Geller, S. et al. (2018). The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?. British journal of dermatology. p. 571. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Geller, S. et al. (2018). The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?. British journal of dermatology. p. 571. [Online].